, GLOBOCAN. World Health Organization
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer, Ann Oncol. 1 juill, vol.22, issue.7, pp.1507-1526, 2010. ,
, Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-SmallCell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials, J Clin Oncol, vol.26, issue.28, pp.4617-4642, 2008.
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a metaanalysis of the published literature, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.23, issue.13, pp.2926-2962, 2005. ,
Should chemotherapy combinations for advanced nonsmall cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials, Lung Cancer Amst Neth. mars, vol.51, issue.3, pp.335-380, 2006. ,
Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.22, pp.3852-3861, 2004. ,
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, J Natl Cancer Inst. 6 juin, vol.99, issue.11, pp.847-57, 2007. ,
Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer, N Engl J Med. 10 janv, vol.346, issue.2, pp.92-100, 2002. ,
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.26, issue.21, pp.3543-51, 2008. ,
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, The Lancet. sept, vol.378, issue.9796, pp.1079-88, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00718837
, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group, BMJ, vol.311, issue.7010, pp.899-909, 1995.
Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer, N Engl J Med, vol.9, 2006. ,
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed Page, p.61 ,
, by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer, J Clin Oncol. 1 déc, vol.31, issue.34, pp.4349-57, 2013.
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL, J Clin Oncol. 10 mars, vol.27, issue.8, pp.1227-1261, 2009. ,
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy, Clin Cancer Res. 15 févr, vol.16, issue.4, pp.1307-1321, 2010. ,
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma, N Engl J Med. 3 sept, vol.361, issue.10, pp.947-57, 2009. ,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. mars, vol.13, issue.3, pp.239-285, 2012. ,
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUXLung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol. févr, vol.16, issue.2, pp.141-51, 2015. ,
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, N Engl J Med. 16 févr, vol.376, issue.7, pp.629-669, 2017. ,
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med. 11 janv, vol.378, issue.2, pp.113-138, 2018. ,
ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol. 1 août, vol.25, issue.8, pp.1475-84, 2014. ,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med. 20 juin, vol.368, issue.25, pp.2385-94, 2013. ,
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, N Engl J Med. 4 déc, vol.371, issue.23, pp.2167-77, 2014. ,
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, Lancet Oncol. juill, vol.18, issue.7, pp.874-86, 2017. ,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet, vol.389, pp.917-946, 2017. ,
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med. 31 août, vol.377, issue.9, pp.829-867, 2017. ,
Brigatinib vs Crizotinib in patients with ALKinhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 Trial (ALTA-1L). Session plénière présenté à, WCLC, 2018. ,
Crizotinib in ROS1Rearranged Non-Small-Cell Lung Cancer, N Engl J Med, vol.371, issue.21, pp.1963-71, 2014. ,
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2 août, vol.8, 2017. ,
The Hallmarks of Cancer, Cell. 7 janv, vol.100, issue.1, pp.57-70, 2000. ,
Hallmarks of Cancer: The Next Generation, Cell. mars, vol.144, issue.5, pp.646-74, 2011. ,
Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity. juill, vol.39, issue.1, pp.1-10, 2013. ,
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer, Cancer Discov. avr, vol.8, issue.4, pp.395-402, 2018. ,
Lung cancer: potential targets for immunotherapy, Lancet Respir Med. sept, vol.1, issue.7, pp.551-63, 2013. ,
Immunothérapie et cancer du poumon : nouveaux concepts, Rev Mal Respir. juin, vol.35, issue.6, pp.642-51, 2018. ,
The PD-1/PD-L1 (B7-H1) Pathway in Chronic InfectionInduced Cytotoxic T Lymphocyte Exhaustion, BioMed Res Int, 2011. ,
,
PD-1 on dendritic cells impedes innate immunity against bacterial infection, vol.113, pp.5811-5819, 2009. ,
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, Lancet Oncol. janv, vol.15, issue.1, pp.59-68, 2014. ,
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, Lancet Oncol. juin, vol.17, issue.6, pp.822-857, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01868690
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial, Int J Oncol. 24 juin, vol.39, issue.4, pp.1011-1018, 2011. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol. 10 déc, vol.35, issue.35, pp.3924-3957, 2017. ,
Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med. 22 juin, vol.376, issue.25, pp.2415-2441, 2017. ,
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, J Clin Oncol. 1 sept, vol.34, issue.25, pp.2969-79, 2016. ,
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med, vol.31, issue.22, pp.2093-104, 2018. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016. ,
Healthrelated quality-of-life results for pembrolizumab versus chemotherapy in advanced, PDL1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial, Lancet Oncol. déc, vol.18, issue.12, pp.1600-1609, 2017. ,
43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894), J Thorac Oncol, vol.11, issue.10, pp.244-249, 2016. ,
Meeting Library | Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ? 1%: Open-label, phase 3 KEYNOTE-042 study. Plenary session présenté à: ASCO, 2018. ,
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med. 31 mai, vol.378, issue.22, pp.2078-92, 2018. ,
KEYNOTE 407 Pembrolizumab Plus Chemotherapy in Squamous NSCLC-The ASCO Post. ASCO présenté à, 2018. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung ,
, cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.14, issue.24, pp.2288-301, 2018. ,
IMPower 132: PFS and safety results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in stage IV non squamous NSCLC. WCLC présenté à, 2018. ,
Avelumab vs Docetaxel for previously treated advanced NSCLC: primary analysis of the phase 3 JAVELIN Lung, 2018. ,
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.30, pp.3449-57, 2017. ,
Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PDL1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer, Lancet Oncol. mars, vol.17, issue.3, pp.299-308, 2016. ,
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. févr, vol.54, pp.139-187, 2016. ,
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. The BMJ. 14 mars, vol.360, 2018. ,
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol. avr, vol.27, issue.4, pp.559-74, 2016. ,
Current status of DILD in molecular targeted therapies, Int J Clin Oncol. déc, vol.17, issue.6, pp.534-575, 2012. ,
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study, Am J Respir Crit Care Med. 15 juin, vol.177, issue.12, pp.1348-57, 2008. ,
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol Off J Am Soc Clin Oncol. 1 juin, vol.24, issue.16, pp.2549-56, 2006. ,
Immunecheckpoint inhibitors associated with interstitial lung disease in cancer patients, Eur Respir J. 1 août, vol.50, issue.2, p.1700050, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01819272
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis, Ther Adv Respir Dis. juin, vol.10, issue.3, pp.183-93, 2016. ,
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions, Mucosal Immunol. janv, vol.3, issue.1, pp.81-91, 2010. ,
Role of PD-L1 and PD-L2 in allergic diseases and asthma, Allergy. févr, vol.66, issue.2, pp.155-62, 2011. ,
Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N Engl J Med. 22 janv, vol.372, issue.4, pp.320-350, 2015. ,
Nivolumabinduced organizing pneumonitis in a patient with lung sarcomatoid carcinoma, Lung Cancer. sept, vol.99, pp.162-167, 2016. ,
,
Bevacizumab et hypertension artérielle ou protéinurie : prise en charge, Rev Mal Respir. juin, vol.25, issue.6, pp.767-72, 2008. ,
, and by The ERS Executive Committee, International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, vol.165, pp.277-304, 2001.
Traction bronchiectasis in end-stage pulmonary fibrosis, Radiology. déc, vol.161, issue.3, pp.665-674, 1986. ,
From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology?, BMC Pulm Med. 23 mai, vol.16, 2016. ,
Ipilimumab in patients with melanoma and autoimmune disease, J Immunother Cancer, vol.2, issue.1, p.35, 2014. ,
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders, JAMA Oncol. févr, vol.2, issue.2, pp.234-274, 2016. ,
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease, Thorac Cancer. juill, vol.9, issue.7, pp.847-55, 2018. ,
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, vol.350, issue.6264, pp.1079-84, 2015. ,
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab, Ann Oncol. juin, vol.28, issue.6, pp.1368-79, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01604339